SK Biopharmaceuticals Co., Ltd.
326030
Rankning i aktier
#4040
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Aktiekurs
$51.65
Marknadsvärde
$4.05B
Förändring (1 dag)
0.27%
Förändring (1 år)
-30.95%
Land
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Vinst för SK Biopharmaceuticals Co., Ltd. (326030)
Vinst i Jun 2026 TTM: $199.99M
Enligt de senaste finansiella rapporterna från SK Biopharmaceuticals Co., Ltd. är företagets nuvarande vinst $199.99M. År 2024 hade företaget en vinst på $49.38M, en ökning jämfört med vinsten år 2023 som var $-33.88M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för SK Biopharmaceuticals Co., Ltd. från 2011 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $199.99M | 91.48% |
| 2025 | $104.44M | 111.52% |
| 2024 | $49.38M | -245.75% |
| 2023 | $-33.88M | -69.99% |
| 2022 | $-112.90M | -288.31% |
| 2021 | $59.95M | -127.13% |
| 2020 | $-220.98M | 202.16% |
| 2019 | $-73.13M | -40.83% |
| 2018 | $-123.61M | 36.08% |
| 2017 | $-90.84M | 260.75% |
| 2016 | $-25.18M | 14.75% |
| 2015 | $-21.94M | -33.74% |
| 2014 | $-33.12M | -18.07% |
| 2013 | $-40.42M | 43.63% |
| 2012 | $-28.14M | 57.64% |
| 2011 | $-17.85M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | 2,537.63% |
US
|
|
| $-3.09B | -1,643.61% |
US
|
|
| $-4.02B | -2,108.24% |
AU
|
|
| $1.95B | 875.39% |
NL
|
|
| - | - |
CH
|
